Clopidogrel Bisulfate is an oral thienopyridine antiplatelet drug that inhibits platelet aggregation by irreversibly inhibiting the P2Y12 ADP receptor on the platelet surface.

I. CYP2C19 Metabolism Issues

Metabolic mechanism: Clopidogrel is a prodrug that must be converted by the hepatic enzyme CYP2C19 into its active metabolite to exert antiplatelet effects. CYP2C19 gene polymorphism can cause slowed metabolism and reduced efficacy in some patients.

Risk in poor metabolizers: In CYP2C19 poor metabolizers, active metabolite levels after dosing are lower, antiplatelet effects may be weakened, and the risk of thrombosis after stent placement is relatively increased. If possible, genetic testing may be performed, and a physician can assess whether to adjust the regimen.

Drug interactions: Strong CYP2C19 inhibitors such as omeprazole and esomeprazole may reduce the efficacy of clopidogrel and should be avoided; if a proton pump inhibitor is needed, a drug with less impact such as pantoprazole may be selected as instructed by the physician.

II. Bleeding Risk Monitoring

Common bleeding manifestations: During medication, gum bleeding, epistaxis, subcutaneous ecchymosis, increased menstrual volume, etc. may occur; these are generally mild but require close observation.

Be alert to severe bleeding: If black stools, hematemesis, hematuria, headache and vomiting, altered consciousness, etc. occur, they may indicate gastrointestinal or intracranial bleeding, and medical attention should be sought immediately.

High-risk populations: Elderly patients, low-body-weight patients, those with a history of bleeding, and those taking concomitant anticoagulants or nonsteroidal anti-inflammatory drugs have a higher risk of bleeding; monitoring should be strengthened and the drug should be taken as instructed by the physician.

III. Recommendations for Discontinuation Before Surgery

Elective surgery: Generally, it is recommended to stop the drug 5–7 days before elective surgery; the specific timing should be determined by the physician after weighing the type of surgery and the risks of bleeding and thrombosis.

Do not stop the drug on your own: In patients after stent placement, unauthorized discontinuation may lead to stent thrombosis and endanger life; discontinuation must be jointly evaluated by a cardiologist or the surgeon.

Emergency surgery: In case of emergency surgery, proactively inform the physician that you are taking clopidogrel so that appropriate hemostatic or alternative measures can be taken.

These precautions are for reference only. For specific medication plans, please refer to the physician's prescription and the drug package insert.